Kantor, Olga
Burstein, Harold J.
King, Tari A.
Shak, Steven
Russell, Christy A.
Giuliano, Armando E.
Hortobagyi, Gabriel N.
Winer, Eric P.
Korde, Larissa A.
Sparano, Joseph A.
Mittendorf, Elizabeth A. http://orcid.org/0000-0002-9762-8536
Funding for this research was provided by:
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Article History
Received: 29 March 2022
Accepted: 25 June 2022
First Online: 27 July 2022
Disclosure
: Elizabeth A. Mittendorf reports compensated service on scientific advisory boards for AstraZeneca, Exact Sciences, Merck, and Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Genentech; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. She reports the following nonfinancial interests and nonremunerated activities: Board of Directors for the American Society of Clinical Oncology and Scientific Advisor for Susan G. Komen for the Cure Foundation. Tari A. King reports speaker’s honoraria and compensated service on the scientific Advisory Board of Exact Sciences (formerly Genomic Health, Inc.) and compensated service for a Global Advisory Board of Besins Healthcare. Christy A. Russell and Steven Shak report employment by Exact Sciences (formerly Genomic Health, Inc.) and stock ownership of Exact Sciences. Eric P. Winer reports institutional research funding from Genentech/Roche; serving as a consultant for Athenex, Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, Gilead, GlaxoSmithKline, GSK, Jounce, Lilly, St. Lucia, Syros, and Zymeworks; a non-paid scientific advisory board membership at Leap Therapeutics; and serving as President-Elect of ASCO. The remaining authors have no conflicts of interest.